It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation.

However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2.

Genetic deletion of Fyn rescues AD deficits in preclinical models.

This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.

[7] It has furthermore been described that Saracatinib impairs maintenance of human T-cells Acute Lymphoblastic Leukemia by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.